The Expanding Oral Options for LDL Cholesterol Management
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin TherapiesJACC, 2026
- 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of DyslipidemiaJACC, 2026
- Efficacy and Safety of Oral PCSK9 Inhibitor Enlicitide in Adults With Heterozygous Familial HypercholesterolemiaJAMA, 2026
- 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemiasEuropean Heart Journal, 2025
- An Oral PCSK9 Inhibitor for Treatment of HypercholesterolemiaJACC, 2025
- Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant PatientsNew England Journal of Medicine, 2023
- Application of the 2019 ESC/EAS dyslipidaemia guidelines to nationwide data of patients with a recent myocardial infarction: a simulation studyEuropean Heart Journal, 2020
- Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular DiseaseJAMA, 2019